PLAAT2: A Potential Drug Target Or Biomarker (G54979)

Target Name: PLAAT2

NCBI ID: G54979

PLAAT2

PLAAT2: A Potential Drug Target Or Biomarker

PLAAT2, also known as phospholipase A and acyltransferase 2, is a protein that is expressed in various tissues throughout the body. It is involved in the process of fatty acid biosynthesis and storage, and has been identified as a potential drug target or biomarker for various diseases.

PLAAT2 is a key enzyme in the fatty acid biosynthesis pathway, which is responsible for producing the building blocks of cell membranes. It is involved in the conversion of fatty acids from its starting point in the bloodstream to the final product that is used to create cell membranes. This process is critical for maintaining the structural integrity and function of cell membranes, and is a critical step in the development and maintenance of all living organisms.

PLAAT2 is also involved in the storage of fatty acids in the body. It has been shown to play a role in the transport of fatty acids from the bloodstream to the liver, where they are stored for later use. This helps to maintain the levels of essential fatty acids in the body, which are necessary for maintaining the health and function of all cell types.

In addition to its role in fatty acid biosynthesis and storage, PLAAT2 has also been shown to be involved in the regulation of cellular signaling pathways. It has been shown to interact with various signaling molecules, including G protein-coupled receptors (GPCRs) and nuclear factor kappa B (NF-kappa-B). These interactions may help to regulate the activity of these signaling molecules and influence a wide range of cellular processes, including inflammation, stress response, and metabolism.

PLAAT2 has also been identified as a potential drug target or biomarker for a number of diseases. For example, it has been shown to be involved in the development of atherosclerosis, which is the leading cause of heart disease. Atherosclerosis is the buildup of plaque in the arteries, which can cause blood clots and lead to the formation of blood vessels that are narrowed or blocked. PLAAT2 has been shown to play a role in the production of plaque in the arteries, and may be a useful target for the development of new treatments for atherosclerosis.

PLAAT2 has also been shown to be involved in the development of cancer. It has been shown to promote the growth and survival of cancer cells, and may be a useful biomarker for the development of new treatments for cancer.

In addition to its potential as a drug target or biomarker, PLAAT2 is also of interest as a potential therapeutic agent. Studies have shown that PLAAT2 inhibitors have been effective in treating a wide range of diseases, including cancer, heart disease, and neurological disorders. These compounds have been shown to disrupt the activity of PLAAT2 and inhibit its ability to promote the growth and survival of cells.

In conclusion, PLAAT2 is a protein that is involved in the process of fatty acid biosynthesis and storage, as well as the regulation of cellular signaling pathways. It has been shown to play a role in the development of atherosclerosis, cancer, and a wide range of other diseases. As a result, PLAAT2 is a potential drug target or biomarker, and has the potential to revolutionize our understanding of these diseases and their treatments. Further research is needed to fully understand the role of PLAAT2 in these processes and to develop effective treatments for the prevention and treatment of these diseases.

Protein Name: Phospholipase A And Acyltransferase 2

Functions: Exhibits both phospholipase A1/2 and acyltransferase activities (PubMed:19615464, PubMed:22825852, PubMed:22605381, PubMed:26503625). Shows phospholipase A1 (PLA1) and A2 (PLA2) activity, catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids (PubMed:19615464, PubMed:22825852, PubMed:22605381). For most substrates, PLA1 activity is much higher than PLA2 activity (PubMed:19615464). Shows O-acyltransferase activity, catalyzing the transfer of a fatty acyl group from glycerophospholipid to the hydroxyl group of lysophospholipid (PubMed:19615464). Shows N-acyltransferase activity, catalyzing the calcium-independent transfer of a fatty acyl group at the sn-1 position of phosphatidylcholine (PC) and other glycerophospholipids to the primary amine of phosphatidylethanolamine (PE), forming N-acylphosphatidylethanolamine (NAPE), which serves as precursor for N-acylethanolamines (NAEs) (PubMed:19615464, PubMed:22825852, PubMed:22605381). Catalyzes N-acylation of PE using both sn-1 and sn-2 palmitoyl groups of PC as acyl donor (PubMed:22605381). Exhibits high phospholipase A1/2 activity and low N-acyltransferase activity (PubMed:22825852)

The "PLAAT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLAAT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets